GET DAILY SIGNALSWhy Is CVS Health (CVS) Stock Down -10.24% Today?
Key Takeaways
- Shares of CVS fell about 10.24% to roughly $82.05, down from a prior close of $91.41.
- The primary catalyst was the company's announcement that it will split into two independent, publicly traded companies by the first half of 2028, overshadowing an otherwise strong quarterly report.
- Third-quarter results beat expectations, with adjusted EPS of $2.09 versus a $1.65 consensus and revenue of $108.4 billion, while full-year 2026 guidance was raised.
- Investors appeared to focus on execution risk around the separation and structural pressures in retail pharmacy rather than the earnings beat.
- Broader post-election market volatility likely amplified the selling pressure.
- Get more details on Price Targets, Earnings, and Forecast pages to track how the story develops.
- Explore Trending AI Robots to see which AI-driven strategies are positioned for current market conditions.
Opening Summary
CVS Health Corporation, one of the largest U.S. healthcare companies spanning insurance, pharmacy benefit management, and retail pharmacy, saw its stock plunge roughly 10.24% on Tuesday. The shares traded near $82.05, down from the prior session's close of $91.41. The decline came even as the company reported better-than-expected third-quarter results and raised its full-year guidance, with the market instead reacting to management's plan to break the company into two separate, publicly traded entities.
Q3 Earnings Beat and Raised Guidance
The company delivered a strong third quarter, with total revenue rising 5.4% year over year to $108.4 billion, ahead of the roughly $104.75 billion consensus. Adjusted earnings per share came in at $2.09, comfortably above the $1.65 analysts had projected, and GAAP diluted EPS swung to $1.68 from a year-earlier loss of $3.13 that reflected a $5.7 billion goodwill impairment charge.
Management also raised its full-year 2026 adjusted EPS guidance to at least $8.20, up from a prior range of $7.90 to $8.10, and lifted its cash-flow-from-operations outlook to at least $15.5 billion. The Health Care Benefits segment was a standout, with adjusted operating income jumping to $912 million from $314 million a year earlier, while the medical benefit ratio improved to 91.3% from 92.8%. Despite these positive signals, the earnings beat was not enough to sustain the stock.
The Two-Company Split Announcement
The dominant driver of the selloff was the company's plan to separate into two independent, publicly traded companies, a transaction expected to be completed in the first half of 2028 and intended to be tax-free for shareholders. One entity would retain the CVS Health name and house Aetna, CVS Caremark, CVS Specialty, Oak Street Health, and Signify Health, while a second company, CVS Pharmacy, would comprise roughly 9,000 retail locations, mail pharmacy, and MinuteClinic.
While management framed the move as a way to unlock value and sharpen strategic focus, investors reacted cautiously to the execution complexity of a separation of this scale. The retail pharmacy unit continues to face reimbursement pressure and regulatory-driven drug price reductions, and the multi-year timeline leaves room for uncertainty. That skepticism overwhelmed the upbeat quarterly numbers and drove shares sharply lower.
Market Context and Trading Activity
The decline came on elevated volume relative to the stock's recent average, signaling broad-based repositioning rather than a thin, low-liquidity move. The selling also coincided with post-election market volatility, which analysts noted could add to near-term turbulence across equities. Broader healthcare and pharmacy peers faced a mixed session, but the magnitude of CVS's drop reflected company-specific concerns tied to the separation announcement more than sector-wide weakness. The stock gave back a large portion of the gains accumulated in the prior session, breaking below several near-term technical levels in the process.
What Comes Next for CVS
Investors will now watch for further details on the separation structure, leadership transitions, and the expected financial profile of each new entity. Key areas of focus include the ongoing Medicare Advantage margin recovery, retail pharmacy reimbursement trends, and whether management can sustain the improved cash-flow trajectory. Risks remain around elevated medical cost trends and macro headwinds, while the timeline to the planned 2028 split leaves room for shifting execution dynamics.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from hundreds of available strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy, timeframe, performance metrics, and the symbols they trade. Exploring the page can help traders identify automated approaches aligned with today's fast-moving markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CVS in +2.59% Uptrend, growing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CVS moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 160 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 24 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 48 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.467) is slightly lower than the industry average of (3.359). P/E Ratio (23.929) is within average values for comparable stocks, (126.681). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement